Direct and crossover effects of brinzolamide, betaxolol, and latanoprost on choroidal thickness.
Cutan Ocul Toxicol
; 38(2): 196-200, 2019 Jun.
Article
em En
| MEDLINE
| ID: mdl-30719935
ABSTRACT
PURPOSE:
To investigate the acute effects of brinzolamide, betaxolol, and latanoprost (drugs commonly used in the medical management of glaucoma) on choroidal thickness using enhanced depth imaging optical coherence tomography (EDI-OCT).METHODS:
Ninety healthy volunteers were evaluated in this prospective study. Participants were randomly divided into 3 groups. Brinzolamide, betaxolol, and latanoprost were administered into the left eyes of the first group (n = 30), second group (n = 30), and third group (n = 30), respectively, and artificial tear (Sodium hyaluronate) was instilled into the right eyes of all participants. Subfoveal choroidal thickness (SFCT) was measured using EDI-OCT before and 45 minutes after administration of the antiglaucomatous drops.RESULTS:
SFCT revealed a significant increase in the left eye (administered antiglaucomatous drop) in the brinzolamide (p = 0.001) and betaxolol groups (p = 0.049) and a significant increase also in the right eye (administered artificial drop) in the brinzolamide (p = 0.001) and betaxolol groups (p = 0.001). However, SFCT did not reveal a significant increase in the left eye (p = 0.213) or in the right eye (p = 0.062) in the latanoprost group.CONCLUSION:
Brinzolamide and betaxolol caused an increase in SFCT, while latanoprost had no significant effect on SFCT.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sulfonamidas
/
Tiazinas
/
Betaxolol
/
Corioide
/
Latanoprosta
/
Anti-Hipertensivos
Tipo de estudo:
Clinical_trials
/
Observational_studies
Limite:
Adult
/
Humans
/
Middle aged
Idioma:
En
Revista:
Cutan Ocul Toxicol
Assunto da revista:
DERMATOLOGIA
/
OFTALMOLOGIA
/
TOXICOLOGIA
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Turquia